Lilly buys Siga's Priority Review voucher gained via smallpox approval

Eli Lilly and Co. (NYSE:LLY) acquired a Priority Review voucher from Siga Technologies Inc. (NASDAQ:SIGA) for $80 million. The voucher, which Siga obtained in July upon approval of TPOXX tecovirimat to treat smallpox, was the first FDA awarded under its Material Threat Medical Countermeasure voucher program.